Atezolizumab

Category
biologic
Half-Life (t½)
IV: 27d
Aliases
Tecentriq, anti-PD-L1 mAb

Pharmacological Mechanism

Humanised IgG1 mAb with engineered aglycosylated Fc (N297A) targeting PD-L1. Blocks PD-L1 engagement of PD-1 and B7.1, relieving T cell inhibition. Fc aglycosylation eliminates ADCC/CDC so tumour-infiltrating T cells (which also express PD-L1) are not killed. First PD-L1 inhibitor approved.

Half-Life & Elimination Curve (IV: 27d)

100%50%25%12.5%0%0h0×t½27d1×t½54d2×t½81d3×t½108d4×t½135d5×t½0×t½ (0h): 100% remaining (~171 mg/L)1×t½ (27d): 50% remaining (~85.7 mg/L)2×t½ (54d): 25% remaining (~42.9 mg/L)3×t½ (81d): 12.5% remaining (~21.4 mg/L)4×t½ (108d): 6.3% remaining (~10.7 mg/L)5×t½ (135d): 3.1% remaining (~5.36 mg/L)
Elimination (IV)
  • 0×t½0h100% (171 mg/L)
  • 1×t½27d50% (85.7 mg/L)
  • 2×t½54d25% (42.9 mg/L)
  • 3×t½81d12.5% (21.4 mg/L)
  • 4×t½108d6.3% (10.7 mg/L)
  • 5×t½135d3.1% (5.36 mg/L)
Elimination t½27d (IV)
Rate Constant (ke)0.00107 h⁻¹
Est. Peak (Cmax)171 mg/L
Clearance (CL)0.00749 L/h
97% Washout (5×t½)135d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

References